{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T03:05:04Z","timestamp":1779419104590,"version":"3.53.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Medical Excellence Award\u201d Funded by the Creative Research Development Grant from the First Affiliated Hospital of Guangxi Medical University"},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82260469"],"award-info":[{"award-number":["82260469"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15995-3","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T09:05:22Z","timestamp":1776243922000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of PD-1 inhibitor plus induction chemotherapy for nasopharyngeal carcinoma with high-grade extranodal extension: a multicenter retrospective analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Pingting","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xunmei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxiu","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuefeng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fapeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rensheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"issue":"1102","key":"15995_CR1","doi-asserted-by":"publisher","first-page":"20190244","DOI":"10.1259\/bjr.20190244","volume":"92","author":"R Guo","year":"2019","unstructured":"Guo R, Mao YP, Tang LL, Chen L, Sun Y, et al. The evolution of nasopharyngeal carcinoma staging. Br J Radiol. 2019;92(1102):20190244. https:\/\/doi.org\/10.1259\/bjr.20190244.","journal-title":"Br J Radiol"},{"issue":"1","key":"15995_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.radonc.2015.02.017","volume":"115","author":"XS Wang","year":"2015","unstructured":"Wang XS, Hu CS, Ying HM, He XY, Zhu GP, et al. Patterns of lymph node metastasis from nasopharyngeal carcinoma based on the 2013 updated consensus guidelines for neck node levels. Radiother Oncol. 2015;115(1):41\u20135. https:\/\/doi.org\/10.1016\/j.radonc.2015.02.017.","journal-title":"Radiother Oncol"},{"issue":"2","key":"15995_CR3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.6004\/jnccn.2025.0007","volume":"23","author":"AD Colevas","year":"2025","unstructured":"Colevas AD, Cmelak AJ, Pfister DG, Spencer S, Adkins D, et al. NCCN Guidelines\u00ae Insights: Head and Neck Cancers, Version 2.2025. J Natl Compr Canc Netw. 2025;23(2):2\u201311. https:\/\/doi.org\/10.6004\/jnccn.2025.0007.","journal-title":"J Natl Compr Canc Netw"},{"key":"15995_CR4","first-page":"97","volume-title":"Guidelines Working Committee. CSCO Guidelines for Diagnosis and Treatment of Head and neck cancer 2025","author":"Chinese Society of Clinical Oncology (CSCO)","year":"2025","unstructured":"Chinese Society of Clinical Oncology (CSCO). Guidelines Working Committee. CSCO Guidelines for Diagnosis and Treatment of Head and neck cancer 2025. Beijing: People\u2019s Medical Publishing House; 2025. pp. 97\u20139."},{"issue":"12","key":"15995_CR5","doi-asserted-by":"publisher","first-page":"101216","DOI":"10.1016\/j.tranon","volume":"14","author":"X Niu","year":"2021","unstructured":"Niu X, Xue F, Liu P, Hu C, He X. Long-term outcomes of induction chemotherapy followed by intensity-modulated radiotherapy and adjuvant chemotherapy in nasopharyngeal carcinoma patients with N3 disease. Transl Oncol. 2021;14(12):101216. https:\/\/doi.org\/10.1016\/j.tranon.","journal-title":"Transl Oncol"},{"key":"15995_CR6","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.radonc.2021.01.015","volume":"157","author":"YP Mao","year":"2021","unstructured":"Mao YP, Wang SX, Lydiatt W, Shah JP, Colevasetal AD, et al. Unambiguous advanced radiologic extranodal extension determined by MRI predicts worse outcomes in nasopharyngeal carcinoma: Potential improvement for future editions of N category systems. Radiother Oncol. 2021;157:114\u201321. https:\/\/doi.org\/10.1016\/j.radonc.2021.01.015.","journal-title":"Radiother Oncol"},{"issue":"32","key":"15995_CR7","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1080\/14796694.2024.2386926","volume":"20","author":"PT Zhou","year":"2024","unstructured":"Zhou PT, Luo YX, Wang CX, Wang RS. The prognostic implications of radiologic extranodal extension in the lymph nodes of patients with nasopharyngeal cancer. Future Oncol. 2024;20(32):2491\u2013502. https:\/\/doi.org\/10.1080\/14796694.2024.2386926.","journal-title":"Future Oncol"},{"issue":"9","key":"15995_CR8","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1002\/hed.25842","volume":"41","author":"YJ Hu","year":"2019","unstructured":"Hu YJ, Lu TZ, Huang SH, Lin SJ, Chen YB, et al. High-grade radiologic extra-nodal extension predicts distant metastasis in stage II nasopharyngeal carcinoma. Head Neck. 2019;41(9):3317\u201327.","journal-title":"Head Neck"},{"key":"15995_CR9","doi-asserted-by":"publisher","first-page":"106438","DOI":"10.1016\/j.oraloncology.2023.106438","volume":"144","author":"WS Peng","year":"2023","unstructured":"Peng WS, Xing X, Li YJ, Ding JH, Mo M, et al. Prognostic nomograms for nasopharyngeal carcinoma with nodal features and potential indication for N staging system: Validation and comparison of seven N stage schemes. Oral Oncol. 2023;144:106438. https:\/\/doi.org\/10.1016\/j.oraloncology.2023.106438.","journal-title":"Oral Oncol"},{"key":"15995_CR10","doi-asserted-by":"publisher","first-page":"110050","DOI":"10.1016\/j.radonc.2023.110050","volume":"191","author":"QYH Ai","year":"2024","unstructured":"Ai QYH, King AD, Yuan H, Vardhanabhuti V, Mo FKF, et al. Radiologic extranodal extension for nodal staging in nasopharyngeal carcinoma. Radiother Oncol. 2024;191:110050. https:\/\/doi.org\/10.1016\/j.radonc.2023.110050.","journal-title":"Radiother Oncol"},{"key":"15995_CR11","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.radonc.2021.10.018","volume":"165","author":"O Chin","year":"2021","unstructured":"Chin O, Yu E, O\u2019Sullivan B, Su J, Tellier A, et al. Prognostic importance of radiologic extranodal extension in nasopharyngeal carcinoma treated in a Canadian cohort. Radiother Oncol. 2021;165:94\u2013102. https:\/\/doi.org\/10.1016\/j.radonc.2021.10.018.","journal-title":"Radiother Oncol"},{"issue":"12","key":"15995_CR12","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1001\/jamaoncol.2024.4354","volume":"10","author":"JJ Pan","year":"2024","unstructured":"Pan JJ, Mai HQ, Ng WT, Hu CS, Li JG, et al. Ninth Version of the AJCC and UICC Nasopharyngeal Cancer TNM Staging Classification. JAMA Oncol. 2024;10(12):1627\u201335. https:\/\/doi.org\/10.1001\/jamaoncol.2024.4354.","journal-title":"JAMA Oncol"},{"key":"15995_CR13","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.canlet.2020.02.010","volume":"477","author":"J Zhao","year":"2020","unstructured":"Zhao J, Guo C, Xiong F, Yu J, Ge J, et al. Single cell RNA-seq reveals the landscape of tumor and infiltrating immune cells in nasopharyngeal carcinoma[J]. Cancer Lett. 2020;477:131\u201343.","journal-title":"Cancer Lett"},{"issue":"20","key":"15995_CR14","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1001\/jama.2023.20181","volume":"330","author":"HQ Mai","year":"2023","unstructured":"Mai HQ, Chen QY, Chen DP, Hu CS, Yang KY, et al. Toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: the JUPITER-02 randomized clinical trial. JAMA. 2023;330(20):1961\u201370. https:\/\/doi.org\/10.1001\/jama.2023.20181.","journal-title":"JAMA"},{"issue":"8","key":"15995_CR15","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/S1470-2045(21)00302-8","volume":"22","author":"YP Yang","year":"2021","unstructured":"Yang YP, Qu S, Li JG, Hu CS, Xu MJ, et al. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN- 1st): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2021;22(8):1162\u201374. https:\/\/doi.org\/10.1016\/S1470-2045(21)00302-8.","journal-title":"Lancet Oncol"},{"issue":"6","key":"15995_CR16","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.ccell.2023.04.014","volume":"41","author":"YP Yang","year":"2023","unstructured":"Yang YP, Pan JJ, Wang H, Zhao YY, Qu SH, et al. Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: a multicenter phase 3 trial (RATIONALE-309). Cancer Cell. 2023;41(6):1061\u201372. https:\/\/doi.org\/10.1016\/j.ccell.2023.04.014.","journal-title":"Cancer Cell"},{"issue":"10445","key":"15995_CR17","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1016\/S0140-6736(24)00594-4","volume":"403","author":"X Liu","year":"2024","unstructured":"Liu X, Zhang Y, Yang KY, Zhang N, Jin F, et al. Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet. 2024;403(10445):2720\u201331. https:\/\/doi.org\/10.1016\/S0140-6736(24)00594-4.","journal-title":"Lancet"},{"key":"15995_CR18","first-page":"4","volume-title":"Guidelines Working Committee. CSCO Guidelines for Diagnosis and Treatment of Nasopharyngeal Carcinoma 2024","author":"Chinese Society of Clinical Oncology (CSCO)","year":"2024","unstructured":"Chinese Society of Clinical Oncology (CSCO). Guidelines Working Committee. CSCO Guidelines for Diagnosis and Treatment of Nasopharyngeal Carcinoma 2024. Beijing: People\u2019s Medical Publishing House; 2024. pp. 4\u201322."},{"issue":"19","key":"15995_CR19","doi-asserted-by":"publisher","first-page":"5140","DOI":"10.1158\/1078-0432.CCR-20-1695","volume":"26","author":"R Uppaluri","year":"2020","unstructured":"Uppaluri R, Campbell KM, Egloff AM, Zolkind P, Skidmore ZL, et al. Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial. Clin Cancer Res. 2020;26(19):5140\u201352.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"15995_CR20","doi-asserted-by":"publisher","first-page":"100094","DOI":"10.1016\/j.esmoop.2021.100094","volume":"6","author":"W Yao","year":"2021","unstructured":"Yao W, Zhao X, Gong Y, Zhang M, Zhang L, et al. Impact of the combined timing of PD-1\/PD-L1 inhibitors and chemotherapy on the outcomes in patients with refractory lung cancer. ESMO Open. 2021;6(2):100094. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100094.","journal-title":"ESMO Open"},{"issue":"18","key":"15995_CR21","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1001\/jama.2025.1132","volume":"13","author":"YL Liang","year":"2025","unstructured":"Liang YL, Liu X, Shen LF, et al. Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma: The DIPPER Randomized Clinical Trial. JAMA. 2025;13(18):1589\u201398. https:\/\/doi.org\/10.1001\/jama.2025.1132.","journal-title":"JAMA"},{"issue":"12","key":"15995_CR22","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S1470-2045(24)00504-7","volume":"25","author":"SL Liu","year":"2024","unstructured":"Liu SL, Li XY, Yang JH, et al. Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trial[J]. Lancet Oncol. 2024;25(12):1563\u201375.","journal-title":"Lancet Oncol"},{"issue":"4","key":"15995_CR23","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S1470-2045(20)30737-3","volume":"22","author":"NY Lee","year":"2021","unstructured":"Lee NY, Ferris RL, Psyrri A, Haddad RI, Tahara M, et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 2021;22(4):450\u201362. https:\/\/doi.org\/10.1016\/S1470-2045(20)30737-3.","journal-title":"Lancet Oncol"},{"issue":"5","key":"15995_CR24","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S1470-2045(24)00100-1","volume":"25","author":"JP Machiels","year":"2024","unstructured":"Machiels JP, Tao YG, Licitra L, Burtness B, Tahara M, et al. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2024;25(5):572\u201387. https:\/\/doi.org\/10.1016\/S1470-2045(24)00100-1.","journal-title":"Lancet Oncol"},{"issue":"1","key":"15995_CR25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.annonc.2022.10.006","volume":"34","author":"Y Tao","year":"2023","unstructured":"Tao Y, Biau J, Sun XS, Sire C, Martin L, et al. Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial. Ann Oncol. 2023;34(1):101\u201310. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.006.","journal-title":"Ann Oncol"},{"issue":"19","key":"15995_CR26","doi-asserted-by":"publisher","first-page":"5743","DOI":"10.1158\/1078-0432.CCR-18-2641","volume":"25","author":"JS O\u2019Donnell","year":"2019","unstructured":"O\u2019Donnell JS, Hoefsmit EP, Smyth MJ, Blank CU, Teng MWL. The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment. Clin Cancer Res. 2019;25(19):5743\u201351. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2641.","journal-title":"Clin Cancer Res"},{"issue":"21","key":"15995_CR27","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022;386(21):1973\u201385. https:\/\/doi.org\/10.1056\/NEJMoa2202170.","journal-title":"N Engl J Med"},{"issue":"6","key":"15995_CR28","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMoa2112651","volume":"386","author":"P Schmid","year":"2022","unstructured":"Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, et al. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N Engl J Med. 2022;386(6):556\u201367. https:\/\/doi.org\/10.1056\/NEJMoa2112651.","journal-title":"N Engl J Med"},{"issue":"15","key":"15995_CR29","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1158\/1078-0432.CCR-22-0666","volume":"28","author":"ZJ Zhang","year":"2022","unstructured":"Zhang ZJ, Wu B, Peng G, Xiao GX, Huang J, et al. Neoadjuvant Chemoimmunotherapy for the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: A Single-Arm Phase 2 Clinical Trial. Clin Cancer Res. 2022;28(15):3268\u201376. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-0666.","journal-title":"Clin Cancer Res"},{"key":"15995_CR30","doi-asserted-by":"publisher","unstructured":"Rosenberg AJ, Juloori A, Jelinek MJ, Agrawal N, Cursio JF, et al. Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer: The DEPEND Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2025;e250081. https:\/\/doi.org\/10.1001\/jamaoncol.2025.0081.","DOI":"10.1001\/jamaoncol.2025.0081"},{"key":"15995_CR31","doi-asserted-by":"publisher","unstructured":"BOURHIS J, AUP\u00e9RIN A, BOREL C et al. Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial [J]. The Lancet. https:\/\/doi.org\/10.1016\/S0140-6736(25)01850-1","DOI":"10.1016\/S0140-6736(25)01850-1"},{"issue":"1","key":"15995_CR32","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1056\/NEJMoa2415434","volume":"393","author":"R Uppaluri","year":"2025","unstructured":"Uppaluri R, Haddad RI, Tao YG, et al. Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer. N Engl J Med. 2025;393(1):37\u201350. https:\/\/doi.org\/10.1056\/NEJMoa2415434.","journal-title":"N Engl J Med"},{"issue":"7","key":"15995_CR33","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00262-024-03698-2","volume":"73","author":"YN Jin","year":"2024","unstructured":"Jin YN, Qiang MY, Wang Y, Lin YJ, Jiang RW, et al. The efficacy and safety of adding PD-1 blockade to induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) for locoregionally advanced nasopharyngeal carcinoma: an observational, propensity score-matched analysis. Cancer Immunol Immunother. 2024;73(7):125. https:\/\/doi.org\/10.1007\/s00262-024-03698-2.","journal-title":"Cancer Immunol Immunother"},{"key":"15995_CR34","doi-asserted-by":"publisher","first-page":"1415246","DOI":"10.3389\/fimmu.2024.1415246","volume":"15","author":"YF Yu","year":"2024","unstructured":"Yu YF, Lu GZ, Wang RJ, Song YK, Wu SG. Additional PD-1 inhibitor improves complete response to induction chemotherapy in locally advanced nasopharyngeal carcinoma. Front Immunol. 2024;15:1415246. https:\/\/doi.org\/10.3389\/fimmu.2024.1415246.","journal-title":"Front Immunol"},{"issue":"9","key":"15995_CR35","doi-asserted-by":"publisher","first-page":"5082","DOI":"10.4049\/jimmunol.1001821","volume":"185","author":"QF Zhou","year":"2010","unstructured":"Zhou QF, Xiao HY, Liu YJ, Peng YB, Hong Y, et al. Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization. J Immunol. 2010;185(9):5082\u201392. https:\/\/doi.org\/10.4049\/jimmunol.1001821.","journal-title":"J Immunol"},{"key":"15995_CR36","doi-asserted-by":"publisher","first-page":"6","DOI":"10.11604\/pamj.2022.41.6.28946","volume":"41","author":"IEL Alami","year":"2022","unstructured":"Alami IEL, Gihbid A, Charoute H, Khaali W, Brahim SM, et al. Prognostic value of Epstein-Barr virus DNA load in nasopharyngeal carcinoma: a meta-analysis. Pan Afr Med J. 2022;41:6. https:\/\/doi.org\/10.11604\/pamj.2022.41.6.28946.","journal-title":"Pan Afr Med J"},{"issue":"3","key":"15995_CR37","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/bjc.2015.467","volume":"114","author":"S Diem","year":"2016","unstructured":"Diem S, Kasenda B, Spain L, Martin-Liberal J, Marconcini R, et al. Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. Br J Cancer. 2016;114(3):256\u201361. https:\/\/doi.org\/10.1038\/bjc.2015.467.","journal-title":"Br J Cancer"},{"issue":"1","key":"15995_CR38","doi-asserted-by":"publisher","first-page":"2453091","DOI":"10.1080\/07853890.2025.2453091","volume":"57","author":"KP Wu","year":"2025","unstructured":"Wu KP, Li QQ, Luo XQ, Wang XX, Lai YZ, et al. Chemoimmunotherapy as induction treatment in concurrent chemoradiotherapy for patients with nasopharyngeal carcinoma stage IVa. Ann Med. 2025;57(1):2453091. https:\/\/doi.org\/10.1080\/07853890.2025.2453091.","journal-title":"Ann Med"},{"issue":"8","key":"15995_CR39","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","volume":"25","author":"KE Yost","year":"2019","unstructured":"Yost KE, Satpathy AT, Wells DK, Qi YY, Wang CL, et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat Med. 2019;25(8):1251\u20139. https:\/\/doi.org\/10.1038\/s41591-019-0522-3.","journal-title":"Nat Med"},{"issue":"9","key":"15995_CR40","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/S1470-2045(21)00333-8","volume":"22","author":"XX Zhou","year":"2021","unstructured":"Zhou XX, Yao ZR, Bai H, Duan JC, Wang ZJ, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. Lancet Oncol. 2021;22(9):1265\u201374.","journal-title":"Lancet Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15995-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15995-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15995-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T02:18:18Z","timestamp":1779416298000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15995-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15995"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15995-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"17 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The experimental protocol was established, according to the ethical guidelines of the Helsinki Declaration and was approved by the Human Ethics Committee of The First Affiliated Hospital of Guangxi Medical University (Approval No. 2024-E0343). Written informed consent was obtained from individual or guardian participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"669"}}